Stay updated with breaking news from Athersys Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Athersys (NASDAQ:ATHX – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. The brokerage currently has a $0.75 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective would suggest a potential upside […]
/PRNewswire/ -- The "Cell and Gene Therapy World Market and Market Potential" report has been added to ResearchAndMarkets.com's offering. The report examines...
Athersys (NASDAQ:ATHX – Get Rating) posted its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02), MarketWatch Earnings reports. During the same period in the previous year, the firm earned ($0.11) EPS. Shares of NASDAQ:ATHX opened at $0.69 on Wednesday. The stock […]
Equities analysts expect Athersys, Inc. (NASDAQ:ATHX – Get Rating) to announce earnings of ($0.07) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Athersys’ earnings, with the lowest EPS estimate coming in at ($0.09) and the highest estimate coming in at ($0.05). Athersys posted earnings of […]
Goldman Sachs Group Inc. decreased its position in Athersys, Inc. (NASDAQ:ATHX – Get Rating) by 56.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 203,558 shares of the biopharmaceutical company’s stock after selling 265,805 shares during the period. Goldman […]